Penny Stock Columns on the OTCBB

More Patent Allowances for Provectus Pharmaceuticals' PH-10

04-17-2008

by Lester Young

The European Union has granted a patent application allowance to Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) for its PH-10 dermatology agent and other related agents, along with their uses. The company has also been granted a patent application allowance in Canada for applicator devices used with PH-10.

These pending patents follow recent patents issued in the United States and India for PH-10, a topical product for the treatment of skin diseases such as eczema and psoriasis. Provectus currently holds an international portfolio of twenty-seven patents with five additional pending, in addition to a U.S. portfolio consisting of nineteen issued patents with three others pending.

Provectus, a development-stage company specializing in safer and less invasive dermatology and oncology therapies which are also more effective and economical than traditional methods, is currently assaying the PH-10 agent in Phase 2 clinical trials for the treatment of moderate to severe psoriasis. The company is also engaged in Phase 2 testing of its proprietary PV-10 oncology drugs for treatment of metastatic melanoma, and has received "orphan drug designation" from the U.S. Food and Drug Administration. (The orphan drug designation provides financial incentives to encourage companies to develop necessary drugs to combat rare diseases, where such development would normally be financially disadvantageous.) The new patents will further strengthen Provectus's push for maximum ownership rights of these new products, which may soon be sold in major markets around the world.

The writer does not own shares in the above stocks.

About Pennycents Magazine

Pennycents.com is a mailed monthly magazine featuring Penny Stock companies listed primarily on the OTCBB and Pink Sheets, as well as on Nasdaq, the NYSE, and the AMEX. This independent magazine features information-based articles on publicly-traded reporting companies. Neither Pennycents, its staff or its writers are allowed to invest in companies featured in Pennycents. Pennycents does not accept payment from the companies that are the subjects of its articles or columns. It is the Mission of Pennycents Magazine to be a truly unbiased Penny Stock information platform. You can have Pennycents mailed to your door or learn more by visiting its website: http://www.pennycents.com/ver04/columns.html .

PC Capital Holdings, LLC (Pennycents) believes the information contained herein to be accurate and reliable as of the issue publication date. The information contained herein is not guaranteed or warranted by Pennycents to be accurate, and should not be considered to be all-inclusive. The companies that are written about in Pennycents have not approved the statements made in this disclaimer. Information contained herein may contain forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or a solicitation of an offer to buy or sell securities. Pennycents is a magazine and not a licensed broker, broker/dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a licensed broker before purchasing or selling any securities viewed on http://www.pennycents.com or mentioned herein.

Go Back